Put Options

6 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$12.63 - $24.47 $1.31 Million - $2.53 Million
-103,500 Reduced 59.48%
70,500 $1.67 Million
Q3 2023

Nov 14, 2023

BUY
$10.86 - $17.62 $1.84 Million - $2.98 Million
169,400 Added 3682.61%
174,000 $2.59 Million
Q2 2023

Aug 14, 2023

SELL
$7.47 - $10.95 $126,990 - $186,150
-17,000 Reduced 78.7%
4,600 $50,000
Q1 2023

May 15, 2023

BUY
$5.88 - $9.59 $27,636 - $45,073
4,700 Added 27.81%
21,600 $188,000
Q4 2022

Feb 14, 2023

BUY
$3.22 - $6.27 $19,964 - $38,874
6,200 Added 57.94%
16,900 $105,000
Q3 2022

Nov 14, 2022

SELL
$2.77 - $4.25 $277 - $425
-100 Reduced 0.93%
10,700 $37,000

Others Institutions Holding CBAY

About CymaBay Therapeutics, Inc.


  • Ticker CBAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,677,904
  • Description
  • CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...
More about CBAY
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.